Deals
Swedish Orphan in Talks for Partner on Hemophilia Gene Therapy
Sobi is focusing on its next-generation blood-clotting treatments and plans to introduce Elocta for hemophilia A by the end of this year and Alprolix for hemophilia B in the second half of 2016.
Photographer: Colin Cuthbert/Getty ImagesThis article is for subscribers only.
Swedish Orphan Biovitrum AB, a maker of hemophilia treatments, is in discussions with potential partners on developing a gene therapy for the blood-clotting disorder.
The company, known as Sobi, may enter the race to develop a therapy that would fix the genetic defect that causes hemophilia, which would threaten sales of products designed to prevent bleeding. As Sobi doesn’t have expertise in gene therapy, it’s unlikely to develop such a product in-house, Chief Executive Officer Geoffrey McDonough told reporters in a conference call today.